Skip to content
Search

Latest Stories

PDA welcomes government's move to backtrack restricting workers' rights

The Pharmacists' Defence Association (PDA) has welcomed the Westminster government's move to backtracked from their plan to remove a large number of rights and standards and is having to overhaul the Retained EU Law Bill.

This had included a number of employment rights, including TUPE transfers and the Working Time Directive, which had been established in the UK from EU law.


The Bill’s ‘sunset clause’ was originally going to automatically repeal any EU law not enshrined in UK law by the end of 2023. Critics of the Bill were concerned that this gave the government powers to reform or remove laws without normal Parliamentary scrutiny.

"This would have abolished many improvements to workers’ rights which were enacted through the EU legislature," said PDA.

PDA Director, Paul Day said, “Part of the role of the PDA is to be the trade union for pharmacists. Trade unions lead the campaigns to secure laws relating to rights at work and trade unions will now fight to retain them. Though we have won this battle, holiday pay, parental rights and health and safety protections remain vulnerable.

"If a government aims to reduce the rights at work of pharmacists, and others, then we will need to keep fighting those proposals.”

The Working Time Directive is now going to be retained and no major employment rights will be removed at this time.

"However, the government has still stated its intention to reduce record-keeping for working time purposes. The government has also stated its intention to introduce ‘rolled up’ holiday pay and merge two separate leave entitlements into one pot of statutory leave," said PDA.

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less